US EditionBrazil approves world’s first single-dose dengue vaccine
Butantan-DV vaccine showed 91.6% efficacy in trials with over 16,000 volunteers, enabling faster immunization against severe dengue for ages 12–59, officials said.
- On November 27, 2025, Brazilian authorities approved the Butantan Institute's dengue vaccine, with ANVISA authorising its use for ages 12 to 59.
- Amid a record 2024 epidemic, the World Health Organization reported more than 14.6 million cases and almost 12,000 deaths, with half occurring in Brazil as researchers linked the spread to rising temperatures.
- After eight years of testing, the vaccine demonstrated 91.6 per cent efficacy against severe dengue in trials of more than 16,000 clinical trial volunteers across Brazil.
- Health Minister Alexandre Padilha said Brazil secured a deal with WuXi Biologics to deliver approximately 30 million doses in the second half of 2026, and the single-dose vaccine format will allow faster, simpler campaigns.
- Scientists note that Aedes mosquitoes have expanded into new areas, causing dengue cases in Europe and parts of the United States, while Stanford University researchers estimated global warming caused 19 percent of dengue cases in 2024.
24 Articles
24 Articles
Historic: Brazil Approves World's First Single-Dose Dengue Vaccine
Brazil has approved the world’s first single-dose dengue vaccine, marking a historic milestone as dengue cases rise globally amid climate change. The vaccination, known as Butantan-DV, was developed...
Brazil approves locally produced dengue vaccine
Brazil's National Health Surveillance Agency (Anvisa) has approved the final administrative step before the formal registration of the single-dose dengue vaccine developed by the São Paulo-based Butantan Institute for people aged 12 to 59, which protects against all four virus serotypes.
Brazil approves world's first single-dose dengue vaccine
Brazilian authorities on Wednesday approved the world's first single-dose dengue vaccine, which they hailed as a "historic" achievement as cases of the mosquito-borne disease soar globally due to rising temperatures.
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
